Jason Guthrie, MD
Rheumatology · Springfield, ILNPI 1437299682
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,050 of the $98,291 with a category attached, or 80.4%. AbbVie accounts for 85.5% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $22,861 and has fallen 75.7% since, to $5,559 in 2025. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 903 payments — averaging $108.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$84K
- Amgen$5K
- Novartis$2K
- UCB, Inc.$2K
- Bioventus LLC$1K
- Pfizer$859
- plus $4K from 14 others
Across 9 payments — averaging $1118.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$10K
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$79,05080%
- Travel & lodging$1,0581%
- Food & beverage$17,89018%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 220 | $84,050 |
| Amgen(2 entities) | 179 | $4,633 |
| Novartis | 136 | $2,199 |
| UCB, Inc. | 75 | $1,874 |
| Bioventus LLC | 47 | $1,047 |
| Pfizer | 57 | $859 |
| AstraZeneca | 25 | $628 |
| Lilly USA, LLC | 28 | $483 |
| Sandoz | 26 | $376 |
| Genentech USA, Inc. | 28 | $371 |
| Johnson & Johnson | 16 | $358 |
| Sanofi | 12 | $325 |
| E.r. Squibb & Sons, L.L.C. | 17 | $304 |
| Bristol Myers Squibb | 10 | $225 |
| Fresenius Kabi USA, LLC | 11 | $203 |
| Boehringer Ingelheim | 7 | $180 |
| Sanofi-aventis U.S. LLC | 5 | $106 |
| Aurinia Pharma U.S., Inc. | 2 | $37 |
| GSK | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,291 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 186 | $1,254,943 |
| Humira(Cf) PenAdalimumab | 142 | $1,045,053 |
| Enbrel SureclickEtanercept | 56 | $409,445 |
| Orencia ClickjectAbatacept | 27 | $164,211 |
| Humira PenAdalimumab | 14 | $147,463 |
| Humira(Cf)Adalimumab | 21 | $146,730 |
| OtezlaApremilast | 21 | $103,356 |
| KevzaraSarilumab | 23 | $99,272 |
| SimponiGolimumab | 13 | $79,575 |
| Actemra ActpenTocilizumab | 11 | $60,647 |
| MethotrexateMethotrexate Sodium | 742 | $10,249 |
| Hydroxychloroquine Sulfate | 348 | $9,891 |
| Febuxostat | 54 | $7,108 |
| Prednisone | 644 | $3,062 |
| Leflunomide | 79 | $2,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $84,050 | $1,401,673207 claims |
| AmgenOtezla | $4,633 | $103,35621 claims |
| SanofiKevzara | $325 | $99,27223 claims |
| Johnson & JohnsonSimponi | $358 | $79,57513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 rheumatology providers in Illinois.
Other rheumatology in Springfield
- Jeffrey HorvathSpringfield$246K
- Sriya RanatungaSpringfield$17K
- Robert TrappSpringfield$9K
- Timothy LenardoSpringfield$9K
- Manish JainChicago$1.9M
- Lori SiegelBannockburn$1.5M
- Alfonso BelloGlenview$611K
- Theodore PincusChicago$524K
- Angela CrowleyWillowbrook$483K
- Eric RudermanChicago$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.